The calpains inhibitor MDL28170 protects heart against ischemia/reperfusion injury in rats

Gu Xiao-ming,Wu Feng,Zhang Jian-ying,Wang Yue-min,Li Juan,Zhang Shu-miao,Yang Min,Zhou Jing-jun,Gao Feng

DOI: https://doi.org/10.13498/j.cnki.chin.j.ecc.2013.04.018

2013-01-01

Abstract:Objective Our previous studies demonstrated that MDL28170,an inhibitor of calpains,produced protective effects in the isolated heart.This study was to evaluate the effects of MDL28170 on myocardial ischemia/reperfusion injury in vivo.Methods The rat hearts were subjected to 40 min ischemia/2h reperfusion.MDL28170 was given i.v.5min before ischemia at a dose of 3mg/kg b.w.bolus.The infarcts were measured by TTC staining,the apoptotic index was evaluated by TUNEL staining,and the level of plasma lactate dehydrogenase(LDH) and myocardial caspase 3 activities were determined by colorimetric assay kit.Results Compared with the normal,the hearts in ischemia/reperfusion group exhibited increased infarct size,and enhanced plasma LDH activities.More importantly,MDL28170 significantly attenuated these effects induced by ischemia/reperfusion.In addition,the data of TUNEL staining and caspase 3 activities revealed that there was an increase of cell apoptosis in ischemia/reperfusion group,which was also blocked by MDL28170.The last but not the least,MDL28170 had no effects on myocardial infarcts and apoptosis in the normal.Conclusion These results provide evidence that MDL28170 protects heart against ischemia /reperfusion injury in vivo.It also suggests that inhibiting activation of calpains is an effective strategy for myocardial protection.